Biopharmaceutical company Epizyme sets terms for $60 million IPO

By
A A A

Epizyme, a biotech developing therapeutics for patients with genetically defined cancers, announced terms for its IPO on Tuesday. The Cambridge, MA-based company plans to raise $60 million by offering 4.3 million shares at a price range of $13 to $15. At the midpoint of the proposed range, Epizyme would command a market value of $375 million. 

Epizyme, which was founded in 2007 and booked $48 million in sales for the 12 months ended March 31, 2013, plans to list on the NASDAQ under the symbol EPZM. Epizyme initially filed confidentially on March 22, 2013. Citi, Cowen & Company, and Leerink Swann are the joint bookrunners on the deal.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: EPZM

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Stocks

Referenced

Most Active by Volume

112,131,130
  • $74.98 ▲ 5.18%
57,963,905
  • $8.32 ▲ 8.33%
48,392,602
  • $3.45 ▼ 0.29%
45,276,527
  • $36.17 ▲ 4.21%
44,800,927
  • $17.84 ▲ 0.34%
44,539,649
  • $97.03 ▼ 0.16%
44,078,180
  • $15.62 ▲ 0.64%
43,461,551
  • $35.50 ▼ 1.06%
As of 7/24/2014, 04:04 PM